<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749749</url>
  </required_header>
  <id_info>
    <org_study_id>INN-CB-005</org_study_id>
    <nct_id>NCT00749749</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the CollaRx Bupivacaine Implant Compared to the ON-Q Painbuster Following Abdominal Hysterectomy</brief_title>
  <official_title>A Phase II, Randomized, Single-dose, Unblinded Study to Compare the Efficacy and Safety of the CollaRx Bupivacaine Implant With the ON-Q PainBuster Post-op Pain Relief System in Women Following Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innocoll</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innocoll</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the CollaRx Bupivacaine Implant is safe and&#xD;
      effective in reducing the amount of narcotic pain medication needed to control pain during&#xD;
      the first 96 hours after abdominal hysterectomy when compared to the ON-Q PainBuster Post-op&#xD;
      Pain Relief System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hysterectomy is the second most common surgery among women in the United States (US).&#xD;
      Abdominal hysterectomy surgery may be performed to treat benign tumors, such as fibroids,&#xD;
      heavy periods, painful periods and chronic pelvic pain. The most common route for performing&#xD;
      hysterectomy is through an incision in the abdominal wall; however, about 20% are performed&#xD;
      vaginally.Laparoscopic assisted vaginal hysterectomy is performed when warranted.&#xD;
&#xD;
      Bupivacaine is a local anesthetic (pain medication) that has an established safety profile.&#xD;
      Collagen is a protein that is found in all mammals. The CollaRx Bupivacaine implant is a thin&#xD;
      flat sponge made out of collagen that comes from cattle tendons and contains bupivacaine.&#xD;
      When inserted into a surgical site, the collagen breaks down and bupivacaine is released at&#xD;
      the site but very little is absorbed into the blood stream. The high levels of bupivacaine at&#xD;
      the surgical site may result in less pain for several days after surgery.&#xD;
&#xD;
      The ON Q system consists of 1 elastometric pump with a fill volume of 270 mL containing 0.25%&#xD;
      bupivacaine; 1 soaker catheter measuring 12.5 cm in size; and a fill port, tubing, clamp,&#xD;
      filter and flow restrictor. The pump provides positive pressure and is portable. It may be&#xD;
      attached to the patient's dressing or placed in a carrying pouch. The catheter is inserted&#xD;
      directly into the surgical wound providing a continuous flow of bupivacaine into the wound. A&#xD;
      capillary flow restricting orifice located at the end of the tubing controls the flow rate.&#xD;
&#xD;
      This study will compare the total narcotic use in patients with the CollaRx Bupivacaine&#xD;
      Implant with the total narcotic use in patients with the ON Q PainBuster Post op Pain Relief&#xD;
      System after abdominal hysterectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 10, 2008</start_date>
  <completion_date type="Actual">December 22, 2008</completion_date>
  <primary_completion_date type="Actual">December 22, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Amount of Opioid Rescue Analgesia Used</measure>
    <time_frame>0 to 24 hours postoperatively</time_frame>
    <description>Higher value means worse outcome - Higher number reflects a need for more analgesia - For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. Measurement recorded in total Morphine Milligrams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Opioid Rescue Analgesia Used</measure>
    <time_frame>0 to 48 hours postoperatively</time_frame>
    <description>Higher score means worse outcome - Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Amount of Opioid Rescue Analgesia Used</measure>
    <time_frame>0 to 96 hours postoperatively</time_frame>
    <description>Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Use of Opioid Rescue Analgesia (mg) Over 0 to 72 Hours</measure>
    <time_frame>0 to 72 Hours</time_frame>
    <description>Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Opioid Rescue Analgesia</measure>
    <time_frame>0 to 72 hours</time_frame>
    <description>Higher score has a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain Intensity Scores Over Time AT REST</measure>
    <time_frame>Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96</time_frame>
    <description>For the VAS assessment, patients measured their pain intensity at rest using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (mm) Pain Intensity Scores Over Time (After Cough)</measure>
    <time_frame>Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96</time_frame>
    <description>For the VAS assessment, patients measured their pain intensity after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Bupivacaine collagen sponge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ON-ON-Q PainBuster Post-op Pain relief SystemQ system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)</intervention_name>
    <description>The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
    <arm_group_label>Bupivacaine collagen sponge</arm_group_label>
    <other_name>CollRx Bupivacaine Implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ON-Q PainBuster Post-op Pain relief System</intervention_name>
    <description>5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
    <arm_group_label>ON-ON-Q PainBuster Post-op Pain relief SystemQ system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be a woman who is ≥ 18 and ≤ 75 years of age.&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt; 19 and &lt; 40 kg/m2.&#xD;
&#xD;
          -  Has planned an elective total abdominal hysterectomy for reasons other than&#xD;
             malignancies (such as uterine adenocarcinoma, cervical cancer or leiomyosarcoma) to be&#xD;
             performed according to standard surgical technique using a standard incision and under&#xD;
             general anesthesia with the following caveats:&#xD;
&#xD;
               -  Laparoscopic procedures or supraumbilical or Maylard incisions will not be&#xD;
                  allowed.&#xD;
&#xD;
               -  A nonlaparoscopic incision for benign nonhysterectomy gynecological procedures&#xD;
                  (such as myomectomy or adnexal surgery) is acceptable if the surgical indication&#xD;
                  is not to treat pelvic pain.&#xD;
&#xD;
               -  No concomitant vaginal procedures such as anterior and posterior colporrhaphy&#xD;
                  (A&amp;P repairs) are allowed. An abdominal urethropexy and an incidental&#xD;
                  appendectomy will be allowed.&#xD;
&#xD;
          -  Has a risk classification of I, II or III according to the American Society of&#xD;
             Anesthesiologists (ASA).&#xD;
&#xD;
          -  Is nonpregnant (negative pregnancy test at Screening and Day 0 before surgery) and&#xD;
             nonlactating.&#xD;
&#xD;
          -  Is free of other physical or mental conditions that, in the opinion of the&#xD;
             Investigator, may confound quantification of postoperative pain resulting from the&#xD;
             abdominal hysterectomy.&#xD;
&#xD;
          -  Has the ability to read, understand and comply with the study procedures and the use&#xD;
             of the pain scales; is deemed capable of operating a patient controlled analgesia&#xD;
             (PCA) device; and is able to communicate meaningfully with the study staff.&#xD;
&#xD;
          -  Must voluntarily sign and date an informed consent form (ICF), approved by an&#xD;
             Institutional Review Board (IRB), prior to the conduct of any study specific&#xD;
             procedures.&#xD;
&#xD;
          -  Must be able to fluently speak and understand English and be able to provide&#xD;
             meaningful written informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has known hypersensitivity to amide local anesthetics, opioids, bovine products or to&#xD;
             inactive ingredients of the test article or reference product.&#xD;
&#xD;
          -  Has cardiac arrhythmias or atrioventricular (AV) conduction disorders.&#xD;
&#xD;
          -  Concomitantly uses other amide local anesthetics.&#xD;
&#xD;
          -  Concomitantly uses antiarrhythmics (eg, amiodarone), propranolol or strong/moderate&#xD;
             cytochrome P450 (CYP) 3A4 inhibitors or inducers (eg, macrolide antibiotics and&#xD;
             grapefruit juice).&#xD;
&#xD;
          -  Has used long acting analgesics within 24 hours of surgery. Short acting analgesics&#xD;
             such as acetaminophen may be used on the day of surgery but are subject to&#xD;
             preoperative restrictions for oral intake.&#xD;
&#xD;
          -  Has used aspirin or aspirin containing products within 7 days of surgery. Aspirin at a&#xD;
             dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the patient has been on&#xD;
             a stable dose regimen for ≥ 30 days prior to Screening.&#xD;
&#xD;
          -  Has undergone major surgery within 3 months of the scheduled hysterectomy.&#xD;
&#xD;
          -  Requires the use of Seprafilm® or other absorbable adhesion barriers for the scheduled&#xD;
             hysterectomy.&#xD;
&#xD;
          -  Requires any additional surgical procedures either related or unrelated to the&#xD;
             abdominal hysterectomy during the same hospitalization (except for the specific&#xD;
             allowed procedures noted in the Inclusion Criteria).&#xD;
&#xD;
          -  Is required to receive neuraxial (spinal or epidural) opioid analgesics during the&#xD;
             surgery.&#xD;
&#xD;
          -  Has known or suspected history of alcohol or drug abuse or misuse within 3 years of&#xD;
             Screening or evidence of tolerance or physical dependency on opioid analgesics or&#xD;
             sedative hypnotic medications.&#xD;
&#xD;
          -  Has used opioids or tramadol on an extended daily basis (&gt; 7 days) prior to surgery.&#xD;
             Patients who, in the Investigator's opinion, are developing opioid tolerance are to be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Prior</last_name>
    <role>Study Director</role>
    <affiliation>Innocoll</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cusack SL, Minkowitz HS, Kuss M, Jaros M, Hemsen L. A randomized, multicenter, pilot study comparing the efficacy and safety of a bupivacaine-collagen implant (XaraColl(®)) with the ON-Q PainBuster(®) Post-op Pain Relief System following open gynecological surgery. J Pain Res. 2012;5:453-61. doi: 10.2147/JPR.S37310. Epub 2012 Nov 2.</citation>
    <PMID>23152696</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>September 28, 2020</results_first_submitted>
  <results_first_submitted_qc>November 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2020</results_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abdominal Hysterectomy</keyword>
  <keyword>Postoperative pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine Collagen Sponge</title>
          <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
        </group>
        <group group_id="P2">
          <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
          <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat</population>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine Collagen Sponge</title>
          <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
        </group>
        <group group_id="B2">
          <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
          <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="11.50"/>
                    <measurement group_id="B2" value="43.4" spread="41.0"/>
                    <measurement group_id="B3" value="43.3" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Opioid Rescue Analgesia Used</title>
        <description>Higher value means worse outcome - Higher number reflects a need for more analgesia - For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. Measurement recorded in total Morphine Milligrams</description>
        <time_frame>0 to 24 hours postoperatively</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Opioid Rescue Analgesia Used</title>
          <description>Higher value means worse outcome - Higher number reflects a need for more analgesia - For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. Measurement recorded in total Morphine Milligrams</description>
          <population>Intent-to-Treat Population</population>
          <units>Morphine Milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.85" spread="21.57"/>
                    <measurement group_id="O2" value="67.03" spread="32.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Opioid Rescue Analgesia Used</title>
        <description>Higher score means worse outcome - Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
        <time_frame>0 to 48 hours postoperatively</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Opioid Rescue Analgesia Used</title>
          <description>Higher score means worse outcome - Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
          <population>ITT population</population>
          <units>Morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.43" spread="22.770"/>
                    <measurement group_id="O2" value="74.85" spread="35.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Amount of Opioid Rescue Analgesia Used</title>
        <description>Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
        <time_frame>0 to 96 hours postoperatively</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Amount of Opioid Rescue Analgesia Used</title>
          <description>Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
          <population>ITT Population</population>
          <units>Morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.87" spread="28.175"/>
                    <measurement group_id="O2" value="90.77" spread="46.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Use of Opioid Rescue Analgesia (mg) Over 0 to 72 Hours</title>
        <description>Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
        <time_frame>0 to 72 Hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>Total Use of Opioid Rescue Analgesia (mg) Over 0 to 72 Hours</title>
          <description>Higher score means worse outcome. Higher number means more Analgesia was needed. For the first 24 hours after surgery, patients received IV morphine via a PCA pump as rescue analgesia. Patient demand for morphine was recorded. After 24 hours, patients were offered hydrocodone/acetaminophen (maximum could not exceed 8 tablets per 24 hours of the 5/500 mg tablets [40 mg hydrocodone and 4000 mg acetaminophen]) or similar medication as determined by the Investigator for pain until discharge. If oral medication was insufficient for control of pain, IM or IV morphine could be administered.</description>
          <population>ITT population</population>
          <units>Morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.98" spread="25.27"/>
                    <measurement group_id="O2" value="85.36" spread="41.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Opioid Rescue Analgesia</title>
        <description>Higher score has a better outcome</description>
        <time_frame>0 to 72 hours</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Opioid Rescue Analgesia</title>
          <description>Higher score has a better outcome</description>
          <population>Intent-to-Treat Population</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.43" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.33" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Pain Intensity Scores Over Time AT REST</title>
        <description>For the VAS assessment, patients measured their pain intensity at rest using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
        <time_frame>Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Pain Intensity Scores Over Time AT REST</title>
          <description>For the VAS assessment, patients measured their pain intensity at rest using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.2" spread="21.32"/>
                    <measurement group_id="O2" value="74.5" spread="22.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" spread="24.96"/>
                    <measurement group_id="O2" value="66.5" spread="28.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="26.92"/>
                    <measurement group_id="O2" value="68.6" spread="26.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="21.71"/>
                    <measurement group_id="O2" value="60.9" spread="29.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" spread="32.15"/>
                    <measurement group_id="O2" value="45.8" spread="24.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="29.37"/>
                    <measurement group_id="O2" value="35.8" spread="24.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="33.33"/>
                    <measurement group_id="O2" value="38.9" spread="25.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="29.46"/>
                    <measurement group_id="O2" value="50.7" spread="30.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="32.63"/>
                    <measurement group_id="O2" value="40.3" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" spread="32.11"/>
                    <measurement group_id="O2" value="27.8" spread="20.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="27.31"/>
                    <measurement group_id="O2" value="27.9" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="24.79"/>
                    <measurement group_id="O2" value="34.6" spread="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="23.70"/>
                    <measurement group_id="O2" value="19.1" spread="28.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS (mm) Pain Intensity Scores Over Time (After Cough)</title>
        <description>For the VAS assessment, patients measured their pain intensity after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
        <time_frame>Hour 1, 1.5, 2,3,6,9,12,18,24,36,48,72,96</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine Collagen Sponge</title>
            <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
          </group>
          <group group_id="O2">
            <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
            <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
          </group>
        </group_list>
        <measure>
          <title>VAS (mm) Pain Intensity Scores Over Time (After Cough)</title>
          <description>For the VAS assessment, patients measured their pain intensity after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.</description>
          <population>Intent-to-Treat Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" spread="21.41"/>
                    <measurement group_id="O2" value="86.1" spread="21.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="24.54"/>
                    <measurement group_id="O2" value="79.8" spread="25.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="26.25"/>
                    <measurement group_id="O2" value="84.6" spread="24.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1" spread="26.52"/>
                    <measurement group_id="O2" value="77.1" spread="31.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hour 6.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.9" spread="33.51"/>
                    <measurement group_id="O2" value="65.8" spread="28.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="33.07"/>
                    <measurement group_id="O2" value="52.5" spread="28.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="33.33"/>
                    <measurement group_id="O2" value="38.9" spread="25.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5" spread="29.46"/>
                    <measurement group_id="O2" value="50.7" spread="30.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="32.63"/>
                    <measurement group_id="O2" value="40.3" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" spread="32.11"/>
                    <measurement group_id="O2" value="27.8" spread="20.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" spread="27.31"/>
                    <measurement group_id="O2" value="27.9" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="24.79"/>
                    <measurement group_id="O2" value="34.6" spread="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" spread="23.70"/>
                    <measurement group_id="O2" value="19.1" spread="28.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information regarding AEs was collected from the time of hospital admission through Day 30. Normal postoperative sequelae were not considered to be AEs unless they occurred in a more severe form, as judged by the Investigator. Information on AEs was also collected during the Day 8 and Day 30 follow-up calls.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine Collagen Sponge</title>
          <description>Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.&#xD;
Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant): The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride</description>
        </group>
        <group group_id="E2">
          <title>ON-ON-Q PainBuster Post-op Pain Relief SystemQ System</title>
          <description>Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.&#xD;
ON-Q PainBuster Post-op Pain relief System: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Innocoll</name_or_title>
      <organization>Charlene A. Tucker, MS Executive Director, Medical Writing and Document Management</organization>
      <phone>484-406-5211</phone>
      <email>ctucker@innocoll.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

